Patel NS, et al. - Authors ascertained the incidence of thyroid function test abnormalities (TFTAs) retrospectively in patients who received immune-checkpoint inhibitor (ICI) therapy for cancer treatment. Findings suggested a higher incidence of TFTAs with ICI therapy than previously reported. Compared to patients receiving single-agent ICI therapy, a higher incidence of TFTAs was seen in patients with baseline TFTAs and/or who were receiving ipilimumab and nivolumab combination therapy. Especially in patients with baseline TFTAs, more frequent evaluation of thyroid function in the first 8 weeks was suggested.